Domain Therapeutics and Chime Biologics join forces to advance novel anti-CCR8 antibody for cancer immunotherapy

Ontario Industry UpdatesOBIO News
Written By Arsheen Kaur

Domain Therapeutics, a clinical-stage global biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs) and Chime Biologics, a leading Contract Development and Manufacturing Organization (CDMO) that enables its partners’ success in biologics, announced the signing of a manufacturing service agreement for the production of Domain’s best-in-class Treg depleting anti-CCR8 antibody candidate, DT-7012. This phase of manufacturing aims to deliver an effective therapeutic for cancer patients worldwide.

Domain Therapeutics is an OBIO® member and presented at the OBIO® Investment Summit.

Arsheen Kaur
Previous

Fusion Pharmaceuticals to be acquired by AstraZeneca, accelerating development of next-generation radioconjugates to treat cancer
Next

Cosm Medical achieves FDA clearance for Gynethotics™ Pessaries, pioneering the future of personalized pelvic care